Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in Metastatic Neuroendocrine Tumors
NCT00084461Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in Neuroendocrine Neoplasm (NEN), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 4 weeks. Started Mar 2004; status: terminated.
02
Drugs
romidepsin
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00084461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084461.